Researchers at IBEC help identifying a drug in clinical phase that blocks the effects of SARS-Co-V2
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
The treatment, which can be tested on two hundred Covid-19 patients as of today, has proven effective in mini-kidneys generated from human stem cells. Using hese organoids generated by bioengineering techniques, it has been deciphered how SARS-Co-V2 interacts and infects human kidney cells.
IBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origin of the Coronavirus 2019 disease.
IBEC appears on the catalan news on TV3, where they summarise the various Catalan initiatives to fight against Covid-19.
Several media channels have reported this year’s European Research Council grants to various projects being undertaken in Catalonia. Among these projects is that of Xavier Trepat, group leader at IBEC.
Researchers at Institute for Bioengineering of Catalonia (IBEC) have proposed a model that gives important insights into how nanoparticles interact with cells, virus, bacteria or proteins, among others.